Interim Analysis (IA) of a Global Phase 2 Randomized Controlled Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in IgA Nephropathy
November 3, 2022 | American Society of Nephrology (ASN) Kidney Week
Laura Kooienga, Yusuke Suzuki, Bobby Chacko, Muh Geot Wong, Jonathan Barratt, Chris Oh, Manisha Sahay, Mohit Mathur, Xiaofeng Wang, Jill Yarbrough, Brian J G Pereira